MPM Bioimpact LLC Sells 408,695 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX)

MPM Bioimpact LLC reduced its stake in shares of Repare Therapeutics Inc. (NASDAQ:RPTX - Free Report) by 24.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,231,154 shares of the company's stock after selling 408,695 shares during the quarter. MPM Bioimpact LLC owned about 2.90% of Repare Therapeutics worth $1,613,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of RPTX. Barclays PLC grew its position in shares of Repare Therapeutics by 1,471.7% during the 3rd quarter. Barclays PLC now owns 8,330 shares of the company's stock worth $29,000 after buying an additional 7,800 shares during the period. Vontobel Holding Ltd. boosted its position in shares of Repare Therapeutics by 45.8% during the fourth quarter. Vontobel Holding Ltd. now owns 35,000 shares of the company's stock worth $46,000 after purchasing an additional 11,000 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Repare Therapeutics by 2,144,950.0% during the fourth quarter. JPMorgan Chase & Co. now owns 85,802 shares of the company's stock worth $112,000 after purchasing an additional 85,798 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Repare Therapeutics by 204.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 34,423 shares of the company's stock worth $45,000 after purchasing an additional 23,127 shares in the last quarter. Finally, Stifel Financial Corp boosted its position in shares of Repare Therapeutics by 73.1% during the fourth quarter. Stifel Financial Corp now owns 89,500 shares of the company's stock worth $117,000 after purchasing an additional 37,800 shares in the last quarter. 85.09% of the stock is currently owned by institutional investors and hedge funds.

Repare Therapeutics Trading Up 0.8%

Shares of NASDAQ RPTX traded up $0.01 during mid-day trading on Friday, reaching $1.34. 181,449 shares of the company's stock were exchanged, compared to its average volume of 260,582. The firm has a market capitalization of $57.47 million, a price-to-earnings ratio of -0.67 and a beta of 0.85. The business has a fifty day simple moving average of $1.17 and a 200 day simple moving average of $1.68. Repare Therapeutics Inc. has a twelve month low of $0.89 and a twelve month high of $4.29.

Repare Therapeutics (NASDAQ:RPTX - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.10. Repare Therapeutics had a negative return on equity of 40.87% and a negative net margin of 99.76%. Equities research analysts predict that Repare Therapeutics Inc. will post -2.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reduced their price target on shares of Repare Therapeutics from $10.00 to $5.00 and set a "buy" rating on the stock in a research report on Friday, March 7th.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.